Q-omics provides the consensus-scored SNORA70D profile across patient tissues and cancer cell-line models. SNORA70D expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNORA70D is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, SNORA70D RNA expression shows 7,665 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight BLCA, ESCA, and LAML as cancer lineages where SNORA70D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA70D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA70D survival associations across molecular data types. SNORA70D RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA70D RNA expression–survival associations across cancer types. High SNORA70D expression shows unfavorable associations in BLCA, ACC, UCS, MESO, LUSC and OV. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNORA70D RNA expression.
This table summarizes SNORA70D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA70D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA70D shows higher tumor expression in ESCA. The ESCA box plot shows higher SNORA70D RNA expression in tumor versus normal tissue (log2 FC = +1.025, t-test p < 0.001).
This table shows molecular features associated with SNORA70D in patient tissues and cancer cell lines. In patient samples, SNORA70D shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
